MedTrace Logo

Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC)

NCT03075735 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 408

Last updated 2019-02-04

No results posted yet for this study

Summary

PROREPAIR is a prospective multicenter observational cohort study of unselected patients with metastatic Castration Resistant Prostate Cancer (mCRPC) with unknown germline mutational status at study entry and who are candidates to start 1st line treatment with any approved survival-prolonging agent.

The study aims to evaluate the impact of aberrations in DNA-repair genes,(BRCA1, BRCA2, ATM and PALB2 and other genes) on cause-specific survival from the diagnosis of the metastatic castration resistant status and other outcomes.

Conditions

Sponsors & Collaborators

  • Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

    collaborator OTHER

  • Instituto de Investigacion Biomedica de Malaga

    collaborator OTHER

  • Centro Nacional de Investigaciones Oncologicas CARLOS III

    lead OTHER

Principal Investigators

  • David Olmos, MD · Centro Nacional de Investigaciones Oncologicas CARLOS III

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-15
Primary Completion
2018-05-31
Completion
2018-12-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03075735 on ClinicalTrials.gov